Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 3

Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia

Pages
788–795
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A, AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategies for prostate cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: It is a known fact that the role of microRNAs (miRNA) has a very important place in cancer development and progression. miRNAs target a significant part of pathways as well as genes.
📊
Key Findings & Data:Materials and methods: Peripheral blood mononuclear cells (PBMCs) and tissue samples were collected from prostate cancer (PCa) (n:20) and benign prostatic hyperplasia (BPH) (n: 20) patients.
💡
Conclusion & Impact:Conclusion: Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A, AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategies for prostate cancer.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: It is a known fact that the role of microRNAs (miRNA) has a very important place in cancer development and progression. miRNAs target a significant part of pathways as well as genes. This study aimed to compare the differential expression profiles of miRNAs in prostate cancer and benign prostatic hyperplasia patients. Materials and methods: Peripheral blood mononuclear cells (PBMCs) and tissue samples were collected from prostate cancer (PCa) (n:20) and benign prostatic hyperplasia (BPH) (n: 20) patients. Total RNA isolation was performed. As a result of the RNA concentration and purity measurement, each patient group was pooled, and the miRNAs profiles comparison was performed with the Affymetrix Microarray System. Results: In tissue samples, 37 different expressed miRNAs were identified in PCa patients compared to BPH patients. In PBMCs samples, 27 different expressed miRNAs were identified in PCa patients compared to benign prostatic hyperplasia patients. As a result of the comparison of tissue and PBMCs samples, it was determined that down regülated hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 were common miRNAs. 3 (HIF1A, NHS,INSL4) targets identified for hsa-miR-494-3p, 2 (HIF1A, AVRP1A) for hsa-miR-3128, 3 (AVRP1A, NHS, INSL4) for hsa-miR-8084. Conclusion: Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A, AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategies for prostate cancer. The present study may represent the first in-depth analysis of PBMCs and tissue samples miRNA profiles.

🔖

Cite This Article

DEMİR, M., ERGÜN, O., KOŞAR, A., TEPEBAŞI, M. Y., KOŞAR, P. A., SANCER, O. (2022). Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 3, 788–795. https://ajindex.com/articles/609250

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D et al. Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. International Journal of Cancer. 2019; 144 (8): 1941-1953. doi: 10.1002/ijc.31937 2. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. European Urology. 2016; 70 (5): 862-874. doi: 10.1371/journal.pone.0221775 3. Hatcher D, Garrett Daniels IO, Lee P. Molecular mechanisms involving prostate cancer racial disparity. American Journal of Translational Research. 2009; 1 (3): 235. 4. Krasanakis T, Nikolouzakis TK, Sgantzos M, Mariolis-Sapsakos T, Souglakos J et al. Role of anabolic agents in colorectal carcinogenesis: myths and realities. Oncology reports. 2019; 42 (6): 2228-2244. doi: 10.3892/or.2019.7351 5. Mettlin C, Lee F, Drago J, Murphy GP. Project IotACSNPCD: The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991; 67 (12): 2949- 2958. doi: 10.1002/1097-0142(19910615)67:12 3.0.co;2-x 6. Prestigiacomo A, Stamey T. Clinical usefulness of free and complexed PSA. Scandinavian Journal of Clinical and Laboratory Investigation 1995; 55 (221): 32-34. doi: 10.3109/00365519509090561 7. Morote J, Lopez M, Encabo G, De Torres I. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. European Urology. 2000; 37 (5): 537-540. doi: 10.1159/000020190 8.Smith DK, Natasha Venugopal, Martha K. Terris, Bal L. Lokeshwar. The critical role of interleukin-8 chemokine axis in the development of benign prostatic hyperplasia (BPH). In: Proceedings of the American Association for Cancer Research Annual Meeting 2019;
  2. Atlanta, GA, USA. pp. 123. 9. Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian Journal of Andrology. 2015; 17 (2): 212. doi: 10.4103/1008-682X.140966 10. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical Clinics. 2011; 95 (1): 87-100. doi: 10.1016/j.mcna.2010.08.013 11. Ma J, Lin Y, Zhan M, Mann DL, Stass SA et al. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Laboratory Investigation. 2015; 95 (10):1197-1206. doi: 10.1038/labinvest.2015.88 12. Chen S, Liu M, Liang B, Ge S, Peng J et al. Identification of hum